Ruxolitinib (Jakafi)
Small molecule
Evidence outlook
Approved: Myelofibrosis, Polycythemia Vera, Graft-versus-Host Disease, Chronic Graft-versus-Host Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Treatment of myelofibrosis
- Disease-related splenomegaly or symptoms in adults with primary myelofibrosis (Jakavi; also polycythaemia vera and GvHD)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT00952289 NCT00952289 · Myelofibrosis The trial was randomized and double-blind, used matching placebo, enrolled 309 participants, and its imaging-based primary endpoint was met in favor of ruxolitinib (65 vs 1 participants; p<0.0001). However, no primary-endpoint power or sample-size calculation is reported in the available record, so the evidence is rated moderate rather than strong. Registry: NCT00952289 | 3 | Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 (Baseline and Week 24) 2010-11 | Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 (Baseline and Week 24): Ruxolitinib 65 participants | Placebo 1 participants | Partial signal | link ↗ |
View 1 more trial
NCT00934544 NCT00934544 · Myelofibrosis This was a randomized, open-label comparison of ruxolitinib with best available therapy in 219 participants, and its imaging-based primary endpoint was met favorably (28.5% vs 0%; p<0.0001). The evidence is moderate because treatment assignment was not blinded and the supplied record does not report a power calculation, despite the objective primary measurement. Registry: NCT00934544 | 3 | Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 (Baseline, Week 48) 2015-03-04 | Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 (Baseline, Week 48): Ruxolitinib 28.5 Percentage of Participants | Best Available Therapy (BAT) 0 Percentage of Participants | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (27)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (138)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (62)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (76)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (13)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (12)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Early phase / not applicable (1)
What this study did
Appears in other studies (9)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 3 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other JAK1/2 drugs
baricitinib, Ruxolitinib (Opzelura), pumecitinib. Compare all 4 JAK1/2 drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Chronic Graft-versus-Host Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ruxolitinib (Jakafi): this drug | Approved | Small molecule | JAK1/2 | Partial signal | NCT03112603: Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit (Cycle 7 Day 1 (each cycle was comprised of 4 weeks)): Ruxolitinib 49.7 percentage of participants (95% CI 41.8 to 57.6) | Best Available Therapy 25.6 percentage of participants (95% CI 19.1 to 33) | |
| Axatilimab | Approved | Monoclonal antibody | CSF-1R | Weak signal | Featured results are non-efficacy only in this race | |
| Baricitinib (Olumiant) | Approved(overall) | Small molecule | JAK, JAK1/2 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Belumosudil | Approved | Small molecule | Rho-associated kinase (ROCK, pan) | Weak signal | NCT03640481: Overall Response Rate (ORR) (From the date of randomization to the date of first documentation of progression or death due to any cause or data cut-off, whichever occurred first (maximum duration: up to 40.5 months for adult arms and 27.6 months for adolescent arms)): Adult Arm A: Belumosudil 200 mg QD 74 Percentage of participants | Adult Arm B: Belumosudil 200 mg BID 76 Percentage of participants | Adolescent Arm A: Belumosudil 200 mg QD 50 Percentage of participants | Adolescent Arm B: Belumosudil 200 mg BID 100 Percentage of participants | |
| Ibrutinib | Approved | Small molecule | BTK | not yet graded | No reviewed efficacy summary in this indication | |
| Ruxolitinib (Opzelura) | Approved(overall) | Small molecule | JAK1/2 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Pumecitinib | Phase 3(overall) | Small molecule | JAK1/2 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(105 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ruxolitinib (Jakafi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (5)
November 2026 (2)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (46)
January 2027 (3)
February 2027 (2)
April 2027 (4)
What to watch
What to watch
What to watch
What to watch
May 2027 (2)
June 2027 (10)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
July 2027 (2)
August 2027 (2)
What to watch
September 2027 (4)
What to watch
What to watch
What to watch
What to watch
October 2027 (2)
November 2027 (4)
What to watch
What to watch
What to watch
December 2027 (11)
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
What to watch
2028 (27)
January 2028 (4)
What to watch
What to watch
What to watch
What to watch
February 2028 (2)
March 2028 (1)
What to watch
May 2028 (2)
What to watch
What to watch
June 2028 (4)
What to watch
What to watch
What to watch
July 2028 (3)
What to watch
What to watch
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
October 2028 (3)
What to watch
What to watch
What to watch
November 2028 (1)
What to watch
December 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (14)
January 2029 (3)
What to watch
What to watch
What to watch
February 2029 (2)
What to watch
What to watch
May 2029 (4)
What to watch
What to watch
What to watch
What to watch
August 2029 (2)
November 2029 (1)
What to watch
December 2029 (2)
What to watch
What to watch
2030 (6)
June 2030 (3)
What to watch
What to watch
What to watch
September 2030 (1)
What to watch
November 2030 (1)
What to watch
December 2030 (1)
What to watch
2031 (2)
2032 (4)
February 2032 (1)
What to watch
March 2032 (1)
What to watch
April 2032 (1)
What to watch
November 2032 (1)
What to watch
2045 (1)
March 2045 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent